Wisconsin Wealth Advisors LLC Raises Stock Position in AbbVie Inc. $ABBV

Wisconsin Wealth Advisors LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 4.3% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 5,994 shares of the company’s stock after buying an additional 245 shares during the period. AbbVie comprises 1.3% of Wisconsin Wealth Advisors LLC’s holdings, making the stock its 25th biggest position. Wisconsin Wealth Advisors LLC’s holdings in AbbVie were worth $1,113,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Howe & Rusling Inc. grew its stake in shares of AbbVie by 3.5% during the second quarter. Howe & Rusling Inc. now owns 86,365 shares of the company’s stock valued at $16,031,000 after buying an additional 2,957 shares during the last quarter. Miller Financial Services LLC increased its stake in shares of AbbVie by 5.4% in the second quarter. Miller Financial Services LLC now owns 1,241 shares of the company’s stock worth $230,000 after acquiring an additional 64 shares during the period. NFP Retirement Inc. boosted its stake in shares of AbbVie by 3.6% during the 2nd quarter. NFP Retirement Inc. now owns 4,045 shares of the company’s stock worth $751,000 after acquiring an additional 140 shares in the last quarter. Ensign Peak Advisors Inc grew its holdings in AbbVie by 1.5% in the second quarter. Ensign Peak Advisors Inc now owns 2,154,006 shares of the company’s stock valued at $399,827,000 after purchasing an additional 31,590 shares during the period. Finally, Saturna Capital Corp increased its holdings in AbbVie by 0.3% in the 2nd quarter. Saturna Capital Corp now owns 719,013 shares of the company’s stock worth $133,463,000 after acquiring an additional 1,827 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ABBV shares. Hsbc Global Res lowered shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Daiwa Capital Markets upgraded shares of AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price target on the stock in a research note on Thursday, August 7th. Piper Sandler restated an “overweight” rating and set a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Guggenheim lifted their price target on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Finally, DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a report on Tuesday, November 4th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $240.14.

AbbVie Stock Performance

ABBV stock opened at $231.62 on Thursday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The stock’s fifty day moving average is $226.27 and its two-hundred day moving average is $204.77. The stock has a market capitalization of $409.36 billion, a price-to-earnings ratio of 110.75, a PEG ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business’s revenue was up 9.1% on a year-over-year basis. During the same period last year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s payout ratio is currently 524.24%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.